Earnings jump by 4,6 mm EUR to 3,3 mm EUR. Revenues grow more than 20% to 36 mm EUR. New family of afterloaders well received.
Berlin, March 30, 2005. After two years of flat revenue growth, Berlin-based Eckert & Ziegler AG (ISIN DE0005659500), a specialist for radiation related products for the diagnosis and treatment of cancer, has returned to previous growth rates. Net Earnings jumped by 4.6 mm EUR to 3.3 Mio. EUR (2003: minus 1.3 mm EUR), while revenues increased by more than 20% to 36 mm EUR (2003: 29 mm EUR). The equity rate climbed by 3.8 mm EUR to 67%.
The discontinuation and deconsolidation of various biotechnology development activities contributed mostly with about 4.4 Mio. EUR to the earning increase, while 0.2 mm EUR resulted from improvements in the income from continuing operations. The latter rose to 2.3 mm EUR (2003: 2.1 mm EUR), which represents an undiluted earning per share of 0.74 EUR (2003: 0.69 EUR) from continuing operations.
The revenue increase can be mainly attributed to the acquisition of various new businesses in the spring of 2004, among them a family of new cancer irradiation devices (afterloaders) and accessory products for the radiation oncologist. Other areas of growth included radioactive implants for the treatment of early stages of prostate cancer. The complete annual report can be viewed at www.ezag.de.
The Board of Directors